Arthur He
Stock Analyst at HC Wainwright & Co.
(4.35)
# 386
Out of 5,112 analysts
46
Total ratings
53.06%
Success rate
25.31%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Arthur He
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NKTR Nektar Therapeutics | Maintains: Buy | $120 → $135 | $44.00 | +206.82% | 5 | Dec 16, 2025 | |
| VERA Vera Therapeutics | Maintains: Buy | $85 → $90 | $47.69 | +88.72% | 3 | Nov 10, 2025 | |
| ADAG Adagene | Maintains: Buy | $8 → $7 | $1.83 | +282.51% | 11 | Aug 15, 2025 | |
| AUPH Aurinia Pharmaceuticals | Assumes: Buy | $17 | $15.91 | +6.85% | 1 | Jul 30, 2025 | |
| SLDB Solid Biosciences | Reiterates: Buy | $20 | $5.28 | +278.79% | 10 | Jun 17, 2025 | |
| PRME Prime Medicine | Downgrades: Neutral | n/a | $3.60 | - | 8 | May 20, 2025 | |
| BCAB BioAtla | Reiterates: Neutral | n/a | $0.79 | - | 8 | Mar 31, 2025 |
Nektar Therapeutics
Dec 16, 2025
Maintains: Buy
Price Target: $120 → $135
Current: $44.00
Upside: +206.82%
Vera Therapeutics
Nov 10, 2025
Maintains: Buy
Price Target: $85 → $90
Current: $47.69
Upside: +88.72%
Adagene
Aug 15, 2025
Maintains: Buy
Price Target: $8 → $7
Current: $1.83
Upside: +282.51%
Aurinia Pharmaceuticals
Jul 30, 2025
Assumes: Buy
Price Target: $17
Current: $15.91
Upside: +6.85%
Solid Biosciences
Jun 17, 2025
Reiterates: Buy
Price Target: $20
Current: $5.28
Upside: +278.79%
Prime Medicine
May 20, 2025
Downgrades: Neutral
Price Target: n/a
Current: $3.60
Upside: -
BioAtla
Mar 31, 2025
Reiterates: Neutral
Price Target: n/a
Current: $0.79
Upside: -